<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="600">
	<fontspec id="0" size="8" family="Minion" color="#231f20"/>
	<fontspec id="1" size="8" family="Minion" color="#000000"/>
	<fontspec id="2" size="18" family="Minion" color="#231f20"/>
	<fontspec id="3" size="18" family="Minion-Black" color="#231f20"/>
	<fontspec id="4" size="13" family="Minion" color="#231f20"/>
	<fontspec id="5" size="12" family="Minion-Black" color="#231f20"/>
	<fontspec id="6" size="8" family="Minion-Black" color="#231f20"/>
	<fontspec id="7" size="6" family="Minion" color="#231f20"/>
	<fontspec id="8" size="9" family="Minion" color="#231f20"/>
	<fontspec id="9" size="9" family="Minion" color="#231f20"/>
	<fontspec id="10" size="9" family="Minion" color="#000000"/>
	<fontspec id="11" size="6" family="Minion" color="#231f20"/>
	<fontspec id="12" size="9" family="MinionExp" color="#231f20"/>
	<fontspec id="13" size="8" family="LucidaNewMath-Symbol" color="#231f20"/>
	<fontspec id="14" size="9" family="MinionProMath" color="#231f20"/>
	<fontspec id="15" size="10" family="Minion" color="#231f20"/>
	<fontspec id="16" size="10" family="Minion" color="#000000"/>
	<fontspec id="17" size="10" family="MinionExp" color="#231f20"/>
	<fontspec id="18" size="7" family="Minion" color="#231f20"/>
<text top="45" left="51" width="133" height="8" font="0">International Scholarly Research Network</text>
<text top="54" left="51" width="50" height="8" font="0">ISRN Oncology</text>
<text top="64" left="51" width="104" height="8" font="0">Volume 2012, Article ID 815234,</text>
<text top="64" left="157" width="8" height="8" font="1"><a href="">12</a></text>
<text top="64" left="166" width="17" height="8" font="0">pages</text>
<text top="73" left="51" width="81" height="8" font="0">doi:10.5402/2012/815234</text>
<text top="136" left="51" width="98" height="17" font="2"><i>Clinical Study</i></text>
<text top="160" left="51" width="139" height="17" font="3"><b>Diagnostic Role of</b></text>
<text top="158" left="194" width="12" height="12" font="4"><b>18</b></text>
<text top="160" left="206" width="249" height="17" font="3"><b>F-FECH-PET/CT Compared with</b></text>
<text top="180" left="51" width="477" height="17" font="3"><b>Bone Scan in Evaluating the Prostate Cancer Patients Referring</b></text>
<text top="200" left="51" width="223" height="17" font="3"><b>with Biochemical Recurrence</b></text>
<text top="249" left="87" width="81" height="11" font="5"><b>Mustafa Takesh,</b></text>
<text top="247" left="168" width="4" height="8" font="6"><b>1</b></text>
<text top="249" left="175" width="106" height="11" font="5"><b>Khaldoun Odat Allh,</b></text>
<text top="247" left="280" width="4" height="8" font="6"><b>2</b></text>
<text top="249" left="287" width="72" height="11" font="5"><b>Stefan Adams,</b></text>
<text top="247" left="359" width="4" height="8" font="6"><b>3</b></text>
<text top="249" left="366" width="126" height="11" font="5"><b>and Christian Zechmann</b></text>
<text top="247" left="493" width="4" height="8" font="6"><b>1</b></text>
<text top="270" left="87" width="3" height="6" font="7"><i>1</i></text>
<text top="271" left="91" width="421" height="9" font="8"><i>Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany</i></text>
<text top="280" left="87" width="3" height="6" font="7"><i>2</i></text>
<text top="281" left="91" width="386" height="9" font="8"><i>Department of Urology, Heidelberg University Hospital, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany</i></text>
<text top="291" left="87" width="3" height="6" font="7"><i>3</i></text>
<text top="292" left="91" width="339" height="9" font="8"><i>Department of Nuclear Medicine and Radiology, Knappschaft Hospital, 66280 Sulzbach, Germany</i></text>
<text top="310" left="87" width="202" height="9" font="9">Correspondence should be addressed to Mustafa Takesh,</text>
<text top="310" left="291" width="112" height="9" font="10"><a href="mailto:Takesh@stud.uni-heidelberg.de">Takesh@stud.uni-heidelberg.de</a></text>
<text top="328" left="87" width="196" height="9" font="9">Received 11 August 2012; Accepted 29 September 2012</text>
<text top="346" left="87" width="151" height="9" font="9">Academic Editors: G. Gatti and K. Sonoda</text>
<text top="365" left="87" width="462" height="9" font="9">Copyright © 2012 Mustafa Takesh et al. This is an open access article distributed under the Creative Commons Attribution</text>
<text top="375" left="87" width="462" height="9" font="9">License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly</text>
<text top="386" left="87" width="19" height="9" font="9">cited.</text>
<text top="404" left="87" width="6" height="6" font="11">18</text>
<text top="405" left="93" width="456" height="9" font="9">F-FECH-PET/CT has been proved to be an imaging agent for prostate carcinoma. However, its role in detecting the bone metas-</text>
<text top="415" left="87" width="358" height="9" font="9">tases is still blurred owing to the lack of related studies. The purpose of our study was to assess the e</text>
<text top="413" left="444" width="7" height="12" font="12">ﬃ</text>
<text top="415" left="452" width="61" height="9" font="9">cacy of PET with</text>
<text top="414" left="515" width="6" height="6" font="11">18</text>
<text top="415" left="521" width="28" height="9" font="9">F-ethyl-</text>
<text top="426" left="87" width="463" height="9" font="9">choline in assessing the bone status and to compare the results with that of conventional bone scan findings. For this purpose, we</text>
<text top="436" left="87" width="117" height="9" font="9">selected 37 patients (mean age 69</text>
<text top="435" left="204" width="6" height="10" font="13"><i>±</i></text>
<text top="436" left="211" width="339" height="9" font="9">7), who had been referred for restaging purposes due to biochemical recurrences and underwent</text>
<text top="447" left="87" width="17" height="9" font="9">both</text>
<text top="446" left="106" width="6" height="6" font="11">18</text>
<text top="447" left="112" width="437" height="9" font="9">F-FECH-PET/CT and bone scan in a short interval. Generally 18 patients out 37 patients referred with biochemical relapse</text>
<text top="457" left="87" width="309" height="9" font="9">were confirmed to have bone involvement. From 18 confirmed bone involvement cases,</text>
<text top="456" left="398" width="6" height="6" font="11">18</text>
<text top="457" left="404" width="145" height="9" font="9">F-FECH-PET/CT identified correctly the</text>
<text top="467" left="87" width="463" height="9" font="9">bone involvement in 15 cases with overall sensitivity of 83.3%. On the other hand, bone scan identified 17 out of 18 confirmed cases</text>
<text top="478" left="87" width="375" height="9" font="9">with overall sensitivity of 94.4%. The lesion-related results show that the sensitivity of each investigation di</text>
<text top="476" left="462" width="5" height="12" font="12">ﬀ</text>
<text top="478" left="467" width="82" height="9" font="9">ers with the anatomical</text>
<text top="488" left="87" width="141" height="9" font="9">regions, and by comparing both results,</text>
<text top="488" left="229" width="6" height="6" font="11">18</text>
<text top="488" left="236" width="314" height="9" font="9">F-FECH-PET/CT was mostly superior to bone scan; however, without a statistical signif-</text>
<text top="499" left="87" width="28" height="9" font="9">icance (</text>
<text top="497" left="115" width="13" height="12" font="14"><i>P &gt;</i></text>
<text top="499" left="130" width="4" height="9" font="9">0</text>
<text top="497" left="134" width="2" height="12" font="14"><i>.</i></text>
<text top="499" left="136" width="341" height="9" font="9">1). In conclusion, no significant gain in sensitivity was achieved using bone scan compared with</text>
<text top="498" left="479" width="6" height="6" font="11">18</text>
<text top="499" left="485" width="64" height="9" font="9">F-FECH-PET/CT.</text>
<text top="552" left="51" width="77" height="11" font="5"><b>1. Introduction</b></text>
<text top="575" left="51" width="240" height="9" font="15">Carcinoma of the prostate is the most common malignancy</text>
<text top="586" left="51" width="240" height="9" font="15">in men with increased incidence rates owing to the popula-</text>
<text top="598" left="51" width="235" height="9" font="15">tion ageing and the improvement of diagnostic procedures.</text>
<text top="609" left="66" width="225" height="9" font="15">The early detection of the bone metastases is of value in</text>
<text top="620" left="51" width="240" height="9" font="15">making decision regarding the treatment plan, which may</text>
<text top="632" left="51" width="175" height="9" font="15">vary extremely according to the bone status.</text>
<text top="643" left="66" width="225" height="9" font="15">The likelihood of the bone metastases at the first diagno-</text>
<text top="654" left="51" width="240" height="9" font="15">sis varies with the histological score and serum level of pro-</text>
<text top="666" left="51" width="240" height="9" font="15">state-specific antigen, and it is possible to some extent to esti-</text>
<text top="677" left="51" width="240" height="9" font="15">mate the degree of tumor spread in the light of the PSA value.</text>
<text top="689" left="51" width="240" height="9" font="15">Bone involvement is much less frequently involved with</text>
<text top="700" left="51" width="240" height="9" font="15">low PSA level, so that the bone staging is not recommended</text>
<text top="711" left="51" width="240" height="9" font="15">with PSA less than 10 ng/mL, except if there are known bone</text>
<text top="723" left="51" width="220" height="9" font="15">disorders which may later cause false positive findings <a href="">[</a></text>
<text top="723" left="270" width="5" height="9" font="16"><a href="">1</a></text>
<text top="723" left="275" width="5" height="9" font="15"><a href="">–</a></text>
<text top="723" left="280" width="5" height="9" font="16"><a href="">3</a></text>
<text top="723" left="285" width="6" height="9" font="15"><a href="">].</a></text>
<text top="734" left="51" width="240" height="9" font="15">However, in patients with PSA relapse after primary therapy</text>
<text top="553" left="309" width="240" height="9" font="15">it is not easy to be guessed based on PSA values whether the</text>
<text top="564" left="309" width="240" height="9" font="15">bone involvement or another involvement is behind a PSA</text>
<text top="576" left="309" width="25" height="9" font="15">rising.</text>
<text top="587" left="324" width="225" height="9" font="15">In established skeletal involvement,there is a need of</text>
<text top="598" left="309" width="4" height="9" font="15">e</text>
<text top="596" left="313" width="6" height="13" font="17">ﬀ</text>
<text top="598" left="319" width="230" height="9" font="15">ective imaging method to monitor the status progress.</text>
<text top="610" left="309" width="240" height="9" font="15">Bone scan is the widely used screening technique for assess-</text>
<text top="621" left="309" width="240" height="9" font="15">ing the bone status in the most malignancies, and it shows</text>
<text top="633" left="309" width="240" height="9" font="15">mostly high sensitivity in detecting the bone involvement.</text>
<text top="644" left="309" width="240" height="9" font="15">However, it faces a serious disadvantage represented by the</text>
<text top="655" left="309" width="115" height="9" font="15">low specificity. PET/CT with</text>
<text top="654" left="426" width="7" height="7" font="18">18</text>
<text top="655" left="433" width="116" height="9" font="15">F-fluorodeoxyglucose (FDG)</text>
<text top="667" left="309" width="240" height="9" font="15">is known to have general limitation in prostate cancer. PET</text>
<text top="678" left="309" width="133" height="9" font="15">with radiolabeled choline such as</text>
<text top="677" left="444" width="7" height="7" font="18">18</text>
<text top="678" left="451" width="98" height="9" font="15">F-FECH-PET was found</text>
<text top="689" left="309" width="39" height="9" font="15">to be an e</text>
<text top="687" left="347" width="6" height="13" font="17">ﬀ</text>
<text top="689" left="353" width="196" height="9" font="15">ective method in diagnosis of primary and recur-</text>
<text top="701" left="309" width="109" height="9" font="15">rent PCA tumors as well <a href="">[</a></text>
<text top="701" left="418" width="5" height="9" font="16"><a href="">4</a></text>
<text top="701" left="423" width="2" height="9" font="15"><a href="">,</a></text>
<text top="701" left="429" width="5" height="9" font="16"><a href="">5</a></text>
<text top="701" left="434" width="115" height="9" font="15"><a href="">]. </a>Two possible mechanisms</text>
<text top="712" left="309" width="240" height="9" font="15">have been proposed to explain the increased choline uptake</text>
<text top="723" left="309" width="240" height="9" font="15">in prostate cancer cells. The first is increased cell proliferation</text>
<text top="735" left="309" width="240" height="9" font="15">in tumors, because choline is a precursor for the biosynthesis</text>
</page>
</pdf2xml>
